Diamonds and Dogs


Bio Blast Pharma (ORPN)

Bio Blast's stock price flew up over 25% midway through the trading day after the biopharmaceutical company announced the beginning of a Phase 3 study for Cabaletta in Oculopharyngeal Muscular Dystrophy. The company's CEO made a statement claiming that positive signals were seen throughout the tests. Muscle strength tests reported significant improvements over baseline levels. Overall, Bio Blast sees this as a positive signal, and investors seem to agree. ORPN is now trading around 7.20, much higher than its recent drop to 5.10.

Micron Technology (MU)

The memory-chip provider is slumping once again after Morgan Stanley downgraded it to the lowest rating, underweight. Micron is down 4% and has hit its 52-week low of 23.70. Morgan Stanley has also set a price target of $21, implying even more downside for the poorly performing stock. Micron has been hurt by a decline in demand for computers, which is a large portion of its business. Investors are beginning to question whether or not there will be a turnaround in this company's future.  

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.